The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.
View / Open Files
Authors
Smith-Byrne, Karl
Stewart, Isobel D
Butterworth, Adam S
Surendran, Praveen
Achaintre, David
Amiano, Pilar
Bergmann, Manuela M
Gicquiau, Audrey
Gunter, Marc J
Haller, Toomas
Larose, Tricia L
Metspalu, Andres
Rinaldi, Sabina
Vermeulen, Roel
Waldenberger, Melanie
Publication Date
2021-09-20Journal Title
PLoS medicine
ISSN
1549-1277
Volume
18
Issue
9
Language
eng
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Guida, F., Tan, V. Y., Corbin, L. J., Smith-Byrne, K., Alcala, K., Langenberg, C., Stewart, I. D., et al. (2021). The blood metabolome of incident kidney cancer: A case-control study nested within the MetKid consortium.. PLoS medicine, 18 (9) https://doi.org/10.1371/journal.pmed.1003786
Abstract
<h4>Background</h4>Excess bodyweight and related metabolic perturbations have been implicated in kidney cancer aetiology, but the specific molecular mechanisms underlying these relationships are poorly understood. In this study, we sought to identify circulating metabolites that predispose kidney cancer and to evaluate the extent to which they are influenced by body mass index (BMI).<h4>Methods and findings</h4>We assessed the association between circulating levels of 1,416 metabolites and incident kidney cancer using pre-diagnostic blood samples from up to 1,305 kidney cancer case-control pairs from 5 prospective cohort studies. Cases were diagnosed on average 8 years after blood collection. We found 25 metabolites robustly associated with kidney cancer risk. In particular, 14 glycerophospholipids (GPLs) were inversely associated with risk, including 8 phosphatidylcholines (PCs) and 2 plasmalogens. The PC with the strongest association was PC ae C34:3 with an odds ratio (OR) for 1 standard deviation (SD) increment of 0.75 (95% confidence interval [CI]: 0.68 to 0.83, p = 2.6 × 10-8). In contrast, 4 amino acids, including glutamate (OR for 1 SD = 1.39, 95% CI: 1.20 to 1.60, p = 1.6 × 10-5), were positively associated with risk. Adjusting for BMI partly attenuated the risk association for some-but not all-metabolites, whereas other known risk factors of kidney cancer, such as smoking and alcohol consumption, had minimal impact on the observed associations. A mendelian randomisation (MR) analysis of the influence of BMI on the blood metabolome highlighted that some metabolites associated with kidney cancer risk are influenced by BMI. Specifically, elevated BMI appeared to decrease levels of several GPLs that were also found inversely associated with kidney cancer risk (e.g., -0.17 SD change [ßBMI] in 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2) levels per SD change in BMI, p = 3.4 × 10-5). BMI was also associated with increased levels of glutamate (ßBMI: 0.12, p = 1.5 × 10-3). While our results were robust across the participating studies, they were limited to study participants of European descent, and it will, therefore, be important to evaluate if our findings can be generalised to populations with different genetic backgrounds.<h4>Conclusions</h4>This study suggests a potentially important role of the blood metabolome in kidney cancer aetiology by highlighting a wide range of metabolites associated with the risk of developing kidney cancer and the extent to which changes in levels of these metabolites are driven by BMI-the principal modifiable risk factor of kidney cancer.
Sponsorship
British Heart Foundation (RG/18/13/33946, RG/13/13/30194)
Cancer Research UK Programme Grant (C18281/A19169)
NIHR Imperial Biomedical Research Centre (BRC-1215-20014)
World Cancer Research Fund (2014/1193)
European Commission (313010)
Innovative Medicines Initiative (115372)
Wellcome Trust (202802/Z/16/Z)
Diabetes UK (17/0005587)
Medical Research Council (MC_PC_13048, MR/L00002/1)
Identifiers
PMC8496779, 34543281
External DOI: https://doi.org/10.1371/journal.pmed.1003786
This record's URL: https://www.repository.cam.ac.uk/handle/1810/329741
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.